{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-067483","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.101341+00:00","generated_at":"2026-06-01T06:55:43.134674+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Structure Therapeutics reports positive Phase 2a data for obesity drug GSBR-1290","bullets":["GSBR-1290 achieved placebo-adjusted mean weight loss of 6.2% (p<0.0001) in Phase 2a obesity study at 12 weeks.","Capsule to tablet PK study showed up to 6.9% placebo-adjusted weight loss (p<0.0001) with new tablet formulation.","67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% ≥10% loss vs 0% for placebo.","Adverse events were GI-related; discontinuations 5% in Phase 2a and 11% in PK study; no liver injury.","Phase 2b obesity study expected to begin Q4 2024 with ~300 participants using tablet formulation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-067483","json":"https://secwatch.observer/filing/0001104659-24-067483.json","markdown":"https://secwatch.observer/filing/0001104659-24-067483.md","text":"https://secwatch.observer/filing/0001104659-24-067483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924067483/0001104659-24-067483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924067483/tm2414821d7_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:55:43.134674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}